anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides a preparation of traditional Chinese medicine for curing fracture. The present invention is characterized in that the medicinal preparation contains the raw materials with the following weight portions: mastic, myrrh, natural copper, ground beetle, real gelatin, Chinese waxgourd peel, croton and unprocessed rhizoma pinelliae. The present invention is made from natural traditional Chinese herbal medicines by a scientific prescription. The prescription is unique and reasonable and has the synergistic effects of promoting reunion of bone, strengthening tendons and bones, activating blood and promoting menstruation, promoting the flow of qi by warming the channel, relaxing muscles and tendons and reducing the stagnation, nourishing blood and promoting tissue regeneration, regulating qi, alleviating pain, etc. The present invention can prohibit platelet aggregation, improve blood circulation, enhance bone density, speed up the sedimentation rate of bone mineral, promote the bone growth and accelerate fracture heal. In addition, the present invention has the advantages of obvious curing effect, rapid effect, convenient use, etc. The preparation of the present invention can be also used for curing cervical spondylosis, hyperosteogeny and other bone diseases.
The invention concerns a DNA sequence for the genetic therapy of diseases caused by the immune system. The essential components of the DNA sequence consist of an activator sequence, a promoter module and a gene for the active substance. The activator sequence is activated cell or virus-specifically and the promoter module regulates this activation specifically according to the cell cycle. The choice of activator sequence and active substance depends on the indications. The DNA sequence is introduced into a viral or non-viral vector, supplemented by a ligand having affinity for the target cell. Depending on the choice of activator sequence and active substance, the following conditions can be treated by administration of the DNA sequence: the defective formation of blood cells; autoimmune diseases and allergies as well as rejection reactions against transplanted organs; chronic arthritis; viral and parasitic infections as well as the prevention of viral, bacterial and parasitic infections; leukaemias.
A product for retarding and gentle release of substances into the body contains a carrier material which is insoluble or poorly soluble in water and gastrointestinal fluids, an active agent, optionally other agents, and an optional shell which is soluble in water and gastrointestinal fluids. The product is obtained by compressing a spongiform formation (1,2) containing the active agent (4), and finally coating the product with a shell. The volume of the compressed carrier material (1) is = 2 cm3. The carrier material is a viscose sponge which in water or gastrointestinal fluid occupies a volume (2) which is 2-10 (preferably 4-8) times that of the compressed form (1). The carrier material may be a natural, semi-synthetic or synthetic polymer. The carrier may be a long-fibrous, linear colloidal, high molecular mass polymer. The polymer with the fibrous structure is preferably a protein, preferably a scleroprotein, most preferably collagen.
The present invention relates to the modulation of apolipoprotein (a) expression. In particular, provided herein are oligomeric compounds having a conjugate group that target apolipoprotein (a) [ apo (a) ]. In certain embodiments, the apo (a) -targeting oligomeric compound is conjugated to N-acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeted to apo (a) for use in reducing apo (a) to treat, prevent or ameliorate a disease, disorder or condition associated with apo (a) and/or lp (a). Certain diseases, disorders or conditions associated with apo (a) and/or lp (a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein are useful for treating such diseases, disorders, or conditions in an individual in need thereof.
Patients with leukocyte adhesion deficiency or LAD have a deficiency of the leukocyte integrin CD18 on their leukocyte cell surface and suffer from severe bacterial infections. Two patients with LAD were enrolled in a Phase I clinical trial conducted at the University of Washington School of Medicine in 1999 to determine the safety and potential efficacy of using retroviral vectors containing CD18 to transduce and correct their CD34+ peripheral blood stem cells. This protocol aims to continue the long-term follow-up of these patients at the National Cancer Institute where Dr. Hickstein is now a Senior Investigator. Blood samples will be collected at the follow-up visits on the yearly anniversary of the treatment date (either locally or off-site by the patients' personal physicians) for archiving for potential testing for replication competent retrovirus, and for complete blood counts. Patients will also undergo a history and physical examination at these visits. Results from these tests will be forwarded to the investigators who will report to the NIH and FDA.
The present invention discloses a method for fabricating a drug-carrying contact lens. The drug-carrying contact lens comprises a contact lens containing at least one amphiphatic hybrid nanocarrier carrying drug molecules. According to the heat or light sensitivity of the drug molecule, the present invention respectively fabricates an encapsulation-type drug-carrying contact lens and a drug-soaking type drug-carrying contact lens. The present invention uses a highly-biocompatible amphiphatic hybrid nanocarriers having superior drug encapsulation capability to wrap the drug molecules. Thereby, the drug molecules are uniformly distributed in the contact lens and can be gradually and locally released to the eye of the user wearing the contact lens. Therefore, the present invention can prevent or cure ocular diseases with the loss and side effects of the drug being reduced.
This is a Phase 3, multicentre, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of a subcutaneous treatment regimen of anifrolumab versus placebo in participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE) while receiving standard of care (SOC) treatment. Participants must be taking either 1 or any combination of the following: oral glucocorticoids, antimalarial, and/or immunosuppressants. The study will be performed in adult participants of 18 to 70 years of age.

Approximately 360 participants receiving SOC treatment will be randomised in a 1:1 ratio to receive a fixed subcutaneous dose of anifrolumab or placebo administered once weekly via an accessorized prefilled syringe and with the primary endpoint evaluated at Week 52. Subjects who complete Week 52 may enter into open-label extension (OLE). All patients who enter the OLE Period will receive a fixed subcutaneous dose of anifrolumab for up to 52 weeks. Study intervention will be administered SC via an accessorised prefilled syringe (aPFS).
Patients in Placebo Group will receive a placebo of identical appearance, smell and taste, with the same schedule. In addition, patients will receive standard treatment with ursodeoxycholic acid (UDCA) at a dose of 13-15 mg/kg.In addition, patients will receive standard treatment with ursodeoxycholic acid (UDCA) at a dose of 13-15 mg/kg b.w.
Dichlorodiphenyltrichloroethane (DDT) is a broad-spectrum insecticide, widely detected in environments due to its high stability characteristic and long natural half-life period. The adverse impact of DDT exposure on organisms and humans has attracted great concern worldwide. The current study explored the developmental and neurobehavioral toxicity response of DDT in embryonic zebrafish. The embryos were treated with DDT (0, 0.1, 1, 2.5 and 5 µM) during 6 h post fertilization (hpf) to 144 hpf. Our result indicated that DDT exposures increased the embryo hatching rate at 48 and 60 hpf, the larval malformation rate at 120 hpf and mortality rate at 144 hpf. The manifested malformations included uninflated swim bladder, bent spine and tail, deformed liver, and pericardial edema. The 120 hpf larval organs size of the gut and swim bladder was decreased in higher exposed concentration groups. Besides, DDT exposure resulted in hyperactivity for the embryo spontaneous movement at 24 hpf and tremor like movement measured by the free larval activity at 72 hpf, as well as the larval activity at 96 hpf under light-dark transition stimulus. Mechanistic examinations at 120 hpf revealed DDT exposure elevated oxidative stress through MDA formation increase, ATP level decrease as well as antioxidant enzyme genes (sod1 and gpx1a) expression decrease. DDT exposure induced abnormal neurotransmitters expression with DA level increase, 5-HT and NOS level decrease. DDT exposure suppressed the gene expressions involved in axon development (rab33a and nrxn2a) and potassium channel (kcnq2 and kcnq3). Our results suggest that the hyperactivity and tremor like movement in DDT-exposed embryos/larvae may result from oxidative stress involved with neuronal damage.
A method of diagnosis for predisposition or susceptibility to osteoarthritis comprising of determining the presence or absence of a polymorphic risk version of a vitamin D receptor gene in an animal. The polymorphic risk version of the gene being one that does not contain a cleavage site for restriction enzyme TaqI. The method comprises of using PCR techniques to amplify a fragment of exon 9 of the vitamin D receptor gene. The PCR primers used are: 1. CAGAGCATGGACAGGGAGCAAC (3') 2. GCAACTCCTCATGGCTGAGGTCTC (3') to amplify a 740 base pair fragment of exon 9 of Vitamin D receptor gene.
INTRODUCTION: In the last decade, BTK inhibitors and the BCL-2 inhibitor venetoclax have replaced immunochemotherapy in the treatment of CLL.
AREAS COVERED: This review describes the use of BTK inhibitors and BCL2 inhibitors in the treatment of naive and relapsed or refractory CLL, with particular attention to the mechanisms of resistance. It also addresses the management of double-refractory patients, and the discovery of novel drugs. The corpus of papers was obtained by a search of the PubMed and Google Scholar databases for articles in English.
EXPERT OPINION: Covalent BTK inhibitors and venetoclax are commonly recommended for previously-untreated and relapsed/refractory CLL. However, resistance to both drug classes can develop over time. As such, double-refractory patients are difficult to manage and novel approaches are urgently needed.
Additional Cawthorne-Cooksey exercises were prescribed to the EpleyM\&Exe group. The physiotherapist explained and demonstrated the exercises to each patient and the patients practiced the exercises until they performed them correctly. Then the exercises were prescribed twice a day and repeated 10 times for 6 weeks as a home exercise program.
PROBLEM TO BE SOLVED: To obtain the subject composite, safe in prolonged administration and capable of delivering an orally ingested active ingredient only to the colon without elution before arrival thereof at the colon. SOLUTION: This colic delivery composite comprises an active ingredient (e.g. phytins, bifidus bacteria, antioxidant substances or peptides), a core substance containing the active ingredient, an inner layer, coating the core substance and containing a chitosan (β-1,4-poly-D-glucosamine) and having 1-1,000 μm membrane thickness and an outer layer, containing a gastric acid-resistant material (e.g. a wheat gliadin or a zein) and having 5-300 μm membrane thickness. The core substance may be formed of only the active ingredient or together with another excipient (e.g. sugar, starch, cellulose or lactic acid). The daily intake of the objective composite as a preventing agent for carcinoma of the colon is preferably 1-1,000 mg expressed in terms of phytins.
Rupture of a cerebral aneurysm causes subarachnoid hemorrhage (SAH). Blood in the subarachnoid space of the brain can cause irritation of the cerebral blood vessels, leading to constriction of these vessels, a phenomenon known.as vasospasm. Cerebral vasospasm can cause stroke and possibly death. Of all the patients with SAH, approximately 20-40% will suffer from clinical vasospasm and more than 60% of those patients will never get back to their previous functional status. Tools to identify early vasospasm and thus early treatment could greatly decrease the morbidity and mortality following SAH.

Cleaved tau protein is a neuronal marker that has been detected in blood and CSF of stroke patients early in its time course. Since vasospasm can lead to stroke, the purpose of this project is to determine whether increase in cleaved tau protein in blood and/or CSF can predict early stroke from vasospasm. Changes in brain oxygen tension measured by a brain tissue oxygen monitor and cerebral blood flow measured by CT perfusion will be correlated with cleaved tau protein levels and clinical status. Utilizing statistical analysis the levels of Cleaved tau protein, brain oxygen and blood flow during hospitalization will be correlated with patient outcome. Through this study we hope to identify increase in cleaved tau protein and decrease in cerebral blood flow and oxygenation as predictors of early vasospasm. Early detection and treatment of vasospasm could decrease the stroke rate in SAH patients and therefore be of great benefit to society.
Preterm birth remains a leading cause of perinatal mortality and morbidity. Despite advances in obstetric and pediatric care, the incidence of preterm birth has increased by more than 20% in the last two decades. Approximately 12.8% of births are preterm, however these account for more than 75% of all perinatal morbidity and mortality. Currently prophylactic progesterone administration is the most effective method available for the prevention of recurrent preterm birth. Prior studies have examined the impact of progesterone in women with recurrent preterm birth and cervical shortening. The possible use of progesterone in women experiencing active preterm labor may address the highest risk condition, however, there have not been any clinical trials to date examining this use of vaginal progesterone. Inflammation and decidual hemorrhage are among the proposed mechanisms that appear to be related to preterm labor.We will use a double blinded randomized drug placebo design to study the proposed outcomes in women diagnosed with preterm labor and planned to have standard of care tocolytic therapy. Women will be randomized to daily vaginal progesterone gel or placebo and will be maintained on the drug or placebo until delivery or 36 6/7 weeks.
Excessive beta-adrenergic stimulation has been associated with seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, palpitation, nausea, dizziness, fatigue, malaise, and insomnia [see Overdosage (10.2)]. Therefore, Fluticasone Propionate/Salmeterol DISKUS, like all products containing sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.

Salmeterol, a component of Fluticasone Propionate/Salmeterol DISKUS, can produce a clinically significant cardiovascular effect in some patients as measured by pulse rate, blood pressure, and/or symptoms. Although such effects are uncommon after administration of salmeterol at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Large doses of inhaled or oral salmeterol (12 to 20 times the recommended dose) have been associated with clinically significant prolongation of the QTc interval, which has the potential for producing ventricular arrhythmias. Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.
Trauma is a serious public health issue, and remains a major cause of mortality and disability worldwide. The notion that genetic factors contribute to an individual's response to traumatic injury has advanced significantly. Genetic variations in severely injured patients have been linked to mortality, morbidity, and psychological outcomes. We conducted a comprehensive review of beta-adrenergic receptor polymorphisms and their impact on the pathogenetics of traumatic injuries, which could pave the way for a transformational frontier of personalized medicine in neurotrauma. It remains unclear why some individuals are vulnerable to worse outcomes, whereas others are resilient. Although genetic factors may be significant, the intricate interplay between environmental and genetic factors may be responsible for variations in the presentation and outcome after injury. Recent advancements in genetic analysis and molecular physiology have helped to shed light on the causes of such variability. Although exposure to trauma can initiate a cascade of stress-related responses, these responses alone are insufficient to explain etiopathogenesis. Therefore, gaining insights into how trauma and genetic predispositions to adrenergic variations interact at the molecular level to affect an individual's susceptibility and recuperation could provide an essential understanding of the molecular pathogenesis of traumatic injuries. Therefore, it is imperative to identify potential genetic and physiological markers to guide early management and prognosis of trauma. Such knowledge could pave the way for the discovery of novel biomarkers that can identify a transdiagnostic subgroup that is at high risk and requires early intervention. This could lead to the adoption of personalized medical approaches in neurotrauma care.
PURPOSE:To produce a tablet by grinding and blending powder containing dextrin and an oily component, optionally adding another component to give a mixed material for tableting and making the specific gravity of the mixed material higher than that of a material obtained without grinding. CONSTITUTION:Powder containing dextrin and an oily component is ground and blended by Henschel mixer, etc., and optionally another component to give a mixed material for tableting. The specific gravity of the mixed material is made 1.1-2.0 times (preferably 1.2-1.8 times) as heavy as that of a mixed material obtained without grinding, thus tablets are produced in increased tableting properties and improved productivity. A porous dextrin having 7ml/g specific volume when gently dropping 20g dextrin into 300ml measuring cylinder, is preferable as the dextrin in terms of excellent oil absorbing properties. The oily component is preferably a liquid or a solid at normal temperature. The tablet is applicable as a bathing agent.
Pump dispensers are known, in particular for discharging medicinal liquids. Depending on the field of application, it may be very important to reliably detect the normality of the manipulation in order to provide feedback to the user or a third party about this. For this purpose, a method for evaluating a pumping operation is proposed, which is applied to a pump dispenser (10) which has two subunits (12, 14) that can be moved manually relative to one another and which has a pump (20) with a pump chamber that can be reduced by the movement of the subunits (12, 14) from a first, non-actuated end position into a second, actuated end position. In order to reliably detect the actuated second end position, a force with which the subunits (12, 14) are manually moved toward one another is detected by means of a force sensor (64, 84) during the movement of the subunits (12, 14) relative to one another. The time profile of the detected force is evaluated as follows: a force increase that is unique to the arrival of the manipulated second end position is detected. Depending on whether a force increase which is unique for the arrival of the manipulated second terminal position is detected, a signal which is unique for the result is output by an output device in a tactile, acoustic and/or visual manner and/or is transmitted to an external display device via a wireless interface.
Both venlafaxine and escitalopram are FDA-approved treatments with demonstrated efficacy in treating major depression in the general population. Although little formal research has been done in treating patients with depression and breast cancer, these two are the favored treatments among serotonin reuptake inhibitors due to minimal interference with oncotherapy. The choice between prescribing these two study medications will depend upon prior treatment history. Venlafaxine XR will be serially titrated under expert psychopharmacologist tele-guidance from 75 mg to 300 mg daily, depending on clinical response and tolerance. Escitalopram will similarly be dosed between 5 mg and 30 mg daily.
BACKGROUND: The objective of this research was to examine the impact of the monocyte-to-lymphocyte ratio (MLR) on the advancement of hematoma after cerebral contusion.
METHODS: The clinical information and laboratory test findings of people with cerebral contusion were retrospectively analyzed. Using the tertiles of MLR, the study participants were categorized into three groups, enabling the evaluation of the correlation between MLR and the advancement of hematoma after cerebral contusion.
RESULTS: Among the cohort of patients showing progression, MLR levels were significantly higher compared with the nonprogress group (P < 0.001). The high MLR group had a significantly higher proportion of patients with hematoma progression compared with the medium and low MLR groups. However, the medium MLR group had a lower proportion of patients with hematoma progression compared with the low MLR group. High MLR levels were independently linked to a higher risk of hematoma progression (Odds Ratio 3.546, 95% Confidence Interval 1.187-10.597, P = 0.024). By incorporating factors such as Glasgow Coma Scale score on admission, anticoagulant/antiplatelet therapy, white blood cell count, and MLR into the model, the predictive performance of the model significantly improved (area under the curve 0.754).
CONCLUSIONS: Our study suggests that MLR may serve as a potential indicator for predicting the progression of hematoma after cerebral contusion. Further research is necessary to investigate the underlying pathological and physiological mechanisms that contribute to the association between MLR and the progression of hematoma after cerebral contusion and to explore its clinical implications.